Mumbai: Aurobindo Pharma said on 26 June it has received a tentative approval from the United States Food and Drug Administration (USFDA) for Quinapril Hydrochloride and Hydrochlorothiazide tablets used for treating hypertension.
The company has received tentative approval from USFDA for Quinapril Hydrochloride and Hydrochlorothiazide tablets in the strengths of 10mg/12.5mg and 20mg/25mg.
This is the fifth anti-hypertensive of the company bagging USFDA’s nod and with this Aurobindo’s product basket for the US market has gone up to 45, the pharma company informed the Bombay Stock Exchange.
Quinapril Hydrochloride and Hydrochlorothiazide tablets of 10mg/12.5mg, 20mg/12.5mg and 20mg/25mg is the generic equivalent of Accuretic tablets of Pfizer Pharmaceuticals Ltd.
The company further said the Andhra Pradesh High Court has approved the scheme of arrangement for the merger of APL Life Sciences Ltd (APL Life) and Senor Organics Pvt Ltd (Senor) with itself.
However, no shares would be issued by Aurobindo in consideration for the merger as both APL Life and Senor are wholly owned subsidiaries of Aurobindo Pharma.
KPMG India had assisted Aurobindo in the merger process.
Shares of the company were trading at Rs790, down 0.24% on BSE in the morning trade.